Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITDAEPS (Basic)EPS (Weighted Average and Diluted)Income towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) EBT (2022 - 2024)

Summit Therapeutics (SMMT) has disclosed EBT for 3 consecutive years, with -$65.6 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, EBT fell 81.23% year-over-year to -$65.6 million, compared with a TTM value of -$234.7 million through Dec 2024, up 61.51%, and an annual FY2024 reading of -$234.7 million, up 61.84% over the prior year.
  • EBT was -$65.6 million for Q4 2024 at Summit Therapeutics, down from -$60.8 million in the prior quarter.
  • Across five years, EBT topped out at -$15.8 million in Q2 2023 and bottomed at -$537.2 million in Q1 2023.
  • Average EBT over 3 years is -$95.7 million, with a median of -$45.5 million recorded in 2024.
  • Peak annual rise in EBT hit 91.53% in 2024, while the deepest fall reached 297.11% in 2024.
  • Year by year, EBT stood at -$16.9 million in 2022, then plummeted by 113.75% to -$36.2 million in 2023, then tumbled by 81.23% to -$65.6 million in 2024.
  • Business Quant data shows EBT for SMMT at -$65.6 million in Q4 2024, -$60.8 million in Q3 2024, and -$62.7 million in Q2 2024.